Table 3.
Treatment studies using resveratrol for the activation of PGC-1α in mouse models
| Mouse model | Effect on phenotype | Evidence for mitochondrial biogenesis | Reference |
|---|---|---|---|
| The YG8R transgenic mice containing FXN with GAA repeat expansion in intron 1 as model for Friedreich's ataxia | ND, only increased FXN expression | ND | Li et al. (2013) |
| mdx model of DMD (skeletal muscle) | Amelioration of muscle damage and motor performance, increased mortality rate when dosage at 400 mg·kg−1·day−1 | ND | Hori et al. (2011); Selsby et al. (2012); Gordon et al. (2013) |
| mdx model of DMD (cardiac muscle) | Prevention of cardiomyopathy and cardiac function | ND | Kuno et al. (2013) |
| Tg19959 mouse model of AD | Diminished plaque formation in specific brain areas | ND | Karuppagounder et al. (2009) |
| APP/PS1 mouse model of AD | Diminished plaque formation in specific brain areas | ND | Vingtdeux et al. (2010) |
| N171-82Q HD transgenic mouse model of HD | No effect on motor performance and striatal atrophy | + (BAT) | Ho et al. (2010) |
| MTPT-induced mouse model of PD | Neuroprotective effect, amelioration of dopamine levels | ND | Blanchet et al. (2008); Mudo et al. (2012); Lofrumento et al. (2010) |
| SOD1 (G93A) Gurl model of ALS | No effect when administrated via diet (0.06%). Delay of disease onset and prolonged survival when administered via i.p. injection | ND | Markert et al. (2010); Han et al. (2012) |
ND, not determined.